|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008109,
umls-concept:C0012854,
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0020964,
umls-concept:C0032136,
umls-concept:C0042196,
umls-concept:C0086022,
umls-concept:C0205263,
umls-concept:C0225326,
umls-concept:C0332307,
umls-concept:C0442335,
umls-concept:C0884118,
umls-concept:C1705099
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2005-12-6
|
|
pubmed:abstractText |
Immunization involving a DNA vaccine prime followed by an adenovirus type 5 (Ad5) boost elicited a protective immune response against SHIV challenge in monkeys. However, the hepatocellular tropism of Ad5 limits the safety of this viral vector. This study examines the safety and immunogenicity of a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) in BALB/c mice and rhesus monkeys. This novel Ad5/35 vector showed minimal hepatotoxicity after intramuscular administration with the novel Ad5/35 vector. In addition, an Ad5/35 vector expressing HIV Env gp160 protein (Ad5/35-HIV) generated strong HIV-specific immune responses in both animal models. Priming with a DNA vaccine followed by Ad5/35-HIV boosting yielded protection against a gp160-expressing vaccinia virus challenge in BALB/c mice. The Ad5/35-HIV vector was significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector. These findings indicate that an Ad5/35 vector-based HIV vaccine may be of considerable value for clinical use.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0969-7128
|
|
pubmed:author |
pubmed-author:HanY NYN,
pubmed-author:HayakawaTT,
pubmed-author:HondaMM,
pubmed-author:HonmaKK,
pubmed-author:JounaiNN,
pubmed-author:KitamuraKK,
pubmed-author:KlinmanD MDM,
pubmed-author:MizuguchiHH,
pubmed-author:NaganawaSS,
pubmed-author:OkudaKK,
pubmed-author:SahaSS,
pubmed-author:SomeyaKK,
pubmed-author:TakeshitaFF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1769-77
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16079886-AIDS Vaccines,
pubmed-meshheading:16079886-Adenoviridae,
pubmed-meshheading:16079886-Animals,
pubmed-meshheading:16079886-Antibodies, Viral,
pubmed-meshheading:16079886-DNA, Viral,
pubmed-meshheading:16079886-Female,
pubmed-meshheading:16079886-Gene Therapy,
pubmed-meshheading:16079886-Genetic Vectors,
pubmed-meshheading:16079886-HIV Infections,
pubmed-meshheading:16079886-HIV-1,
pubmed-meshheading:16079886-Immunization,
pubmed-meshheading:16079886-Immunization, Secondary,
pubmed-meshheading:16079886-Macaca mulatta,
pubmed-meshheading:16079886-Male,
pubmed-meshheading:16079886-Mice,
pubmed-meshheading:16079886-Mice, Inbred BALB C,
pubmed-meshheading:16079886-Models, Animal,
pubmed-meshheading:16079886-Neutralization Tests,
pubmed-meshheading:16079886-Vaccines, DNA,
pubmed-meshheading:16079886-Vaccinia virus,
pubmed-meshheading:16079886-Viral Proteins,
pubmed-meshheading:16079886-Virus Physiological Phenomena
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
|
|
pubmed:affiliation |
Department of Molecular Biodefense Research, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
